类器官(organoid)是将具有干性的细胞举行三维作育形成的与其泉源组织在结构和功效上高度相似的微型组织,具有自我组织和自我更新的能力。凭证其泉源细胞的差别,类器官可分为正常成体干细胞泉源(adult stem cells, AdSCs)类器官、多醒目细胞(pluripotent stem cells, PSCs)泉源类器官以及肿瘤类器官。
作为一种新型的研究模子,类器官既可以在体外传代作育,又能够维持其泉源组织的异质性和空间特征,在疾病建模和个体化精准治疗中施展着主要的作用。
现在,该平台已建设了多种临床肿瘤组织泉源的类器官作育系统以及正常组织泉源的类器官作育系统,包括尿路上皮癌类器官作育系统及正常尿路上皮类器官作育系统、肺腺癌类器官作育系统及正常肺类器官作育系统、肾癌类器官作育系统及正常肾类器官作育系统、结直肠癌类器官作育系统、甲状腺癌类器官作育系统、鼻咽癌类器官作育系统等。
建设的肿瘤类器官经多组学判断后,建库冻存。作为肿瘤病人体外的“替身”,肿瘤类器官可以展望病人对抗肿瘤药物的反应,为临床个体化治疗提供实验及理论依据。团结单细胞测序手艺及基因编辑手艺可以探讨肿瘤爆发生长以及耐药的分子机制。
1. Lancaster, M.A. and J.A. Knoblich, Organogenesis in a dish: modeling development and disease using organoid technologies. Science, 2014. 345(6194): p. 1247125.
2. Li, M. and J.C. Izpisua Belmonte, Organoids - Preclinical Models of Human Disease. Reply. N Engl J Med, 2019. 380(20): p. 1982.
3. Li, Z., et al., Patient-Derived Upper Tract Urothelial Carcinoma Organoids as a Platform for Drug Screening. Advanced Science, 2021.(accepted)
4. Yu, L., et al., Patient-derived organoids of bladder cancer recapitulate antigen expression profiles and serve as a personal evaluation model for CAR-T cells in vitro. Clin Transl Immunology, 2021. 10(2): p. e1248.
5. Li, Z., et al., Human Lung Adenocarcinoma-Derived Organoid Models for Drug Screening. iScience, 2020. 23(8): p. 101411.
6. Li, Z., et al., Protocol for generation of lung adenocarcinoma organoids from clinical samples. STAR Protocols, 2021. 2: p. 100239.
7. Chen, D., et al., Organoid cultures derived from patients with papillary thyroid cancer. J Clin Endocrinol Metab, 2021.
8. Kim, J., B.-K. Koo, and J.A. Knoblich, Human organoids: model systems for human biology and medicine. Nature Reviews Molecular Cell Biology, 2020. 21(10): p. 571-584.